OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
14
Results
Show all
Save search
Copy query
Show results for
Unknown
(14)
Publication Date
Release Date
2023
(3)
2019
(2)
2015
(2)
2025
(1)
2024
(1)
2021
(1)
2018
(1)
2016
(1)
2014
(1)
2013
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.
Not available
S-EPMC6920224
|
biostudies-literature
Cite
SEOM Clinical Guideline for bone metastases from solid tumours (2016).
Not available
S-EPMC5138247
|
biostudies-literature
Cite
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Not available
S-EPMC6325829
|
biostudies-literature
Cite
Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma.
Not available
S-EPMC8699401
|
biostudies-literature
Cite
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.
Not available
S-EPMC4519584
|
biostudies-literature
Cite
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Not available
S-EPMC10844502
|
biostudies-literature
Cite
Quality of life with palbociclib plus fulvestrant
versus
placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Not available
S-EPMC9893357
|
biostudies-literature
Cite
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
Not available
S-EPMC12010967
|
biostudies-literature
Cite
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Not available
S-EPMC10358451
|
biostudies-literature
Cite
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Not available
S-EPMC3596060
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets